Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)”

13 trials

Showing 13 of 13 results

Not applicableActive Not RecruitingNCT05669794
What this trial is testing

An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World

Who this might be right for
Atopic Dermatitis
AbbVie 300
Large-scale testing (Phase 3)Study completedNCT06224192
What this trial is testing

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Amgen 151
Testing effectiveness (Phase 2)Study completedNCT04365387
What this trial is testing

Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Who this might be right for
Dermatitis, Atopic
Galderma R&D 242
Testing effectiveness (Phase 2)Study completedNCT03921411
What this trial is testing

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

Who this might be right for
Atopic Dermatitis
Galderma R&D 20
Large-scale testing (Phase 3)Ended earlyNCT05882877
What this trial is testing

Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Who this might be right for
Atopic Dermatitis
Amgen 2,621
Large-scale testing (Phase 3)WithdrawnNCT04666675
What this trial is testing

Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

Who this might be right for
Atopic Dermatitis (AD)
AbbVie
Testing effectiveness (Phase 2)Study completedNCT07712536
What this trial is testing

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

Who this might be right for
Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. 24
Large-scale testing (Phase 3)Study completedNCT05633355
What this trial is testing

Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Who this might be right for
Atopic Dermatitis
Amgen 187
Large-scale testing (Phase 3)Study completedNCT05704738
What this trial is testing

Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Who this might be right for
Atopic Dermatitis
Amgen 532
Not applicableActive Not RecruitingNCT05081557
What this trial is testing

Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
AbbVie 873
Not applicableActive Not RecruitingNCT05139836
What this trial is testing

Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting

Who this might be right for
Atopic Dermatitis
AbbVie 634
Not applicableStudy completedNCT05959083
What this trial is testing

Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

Who this might be right for
Atopic Dermatitis (AD)
AbbVie 200
Large-scale testing (Phase 3)Study completedNCT05601882
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
AbbVie 920

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation